Novo Nordisk, the maker of popular weight-loss drugs Ozempic and Wegovy, is partnering with OpenAI to deploy the technology across its operations as it looks to keep pace with rapid expansion in the obesity drug market. The Danish company announced in a statement on Tuesday that it would use AI to analyze complex datasets, identify promising drug candidates…
Politics
·
Novo Nordisk partners with OpenAI in weight loss drug race
CN
CitrixNews Staff
Originally reported by The Hill
Related Articles
Politics
Oil prices dip amid optimism over potential US-Iran deal
Oil prices decreased early Monday amid negotiations between the Trump administration and Iran on reopening the Strait of...
CitrixNews Staff
·
1 hour ago
Politics
Let’s restore meritocracy to the office of the surgeon general
It has become increasingly common to appoint leaders from outside the career ranks of the Public Health Service.
CitrixNews Staff
·
1 hour ago
Politics
The republic has survived 250 years — now we will decide whether it continues
As we approach the 250th birthday of the American experiment, we are confronted with the greatest threat to its survival...
CitrixNews Staff
·
1 hour ago
Politics
Trump blasts ‘weak and ineffective’ critics of potential Iran deal
President Trump on Monday slammed critics of the reported deal the U.S. is negotiating with the Iranian government to br...
CitrixNews Staff
·
1 hour ago